Article Text

Download PDFPDF

3 Polyunsaturated fatty acids (PUFAs) and specialized pro-resolving mediators (SPMs) are decreased in plasma and serum from SLE patients compared to healthy controls
  1. Julia Davis-Porada1,
  2. Charles Serhan2,
  3. Paul Norris2,
  4. Peter Lipsky3 and
  5. Jane Salmon4
  1. 1Hospital for Special Surgery
  2. 2Center for Experimental Therapeutics and Reperfusion Injury Department of Anesthesia, Perioperative and Pain Medicine Brigham and Womens Hospital and Harvard Medical School
  3. 3AMPEL BioSolutions
  4. 4Hospital for Special Surgery, Weill Cornell Medicine


Background Systemic lupus erythematosus (SLE) is an autoimmune disease with persistent, inflammatory mediated organ damage. It has been suggested that omega-3-polyunsaturated fatty acids (PUFAs) are low in SLE patients and that supplementation with omega-3 PUFAs might be beneficial. Omega-3 PUFAs can be metabolized to specialized pro-resolving mediators (SPM) in inflamed tissues. PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), give rise to protectins and E-series and d-series resolvins, respectively. These SPMs help promote tissue repair and healing in addition to reducing neutrophil infiltration. We sought to determine whether EHA and DHA and SPMs were dysregulated in lupus patients compared to controls.

Methods Blood samples were collected from 12 patients enrolled in the Autoimmune Disease Registry and Repository, a single center registry (1996-present) of patients meeting ACR SLE classification criteria. Samples were collected from 12 non-SLE-controls who were age (±5 years) and race/ethnicity matched. Metabolomic profiling via tandem mass spectrometry (LC-MS-MS) was performed on serum and plasma to assess the PUFA and SPM levels.

Results Levels of EPA and DHA were highly correlated in serum and plasma. Both EPA and DHA were significantly decreased in SLE patients compared to controls (table 1). Neither plasma nor serum DHA or EPA levels was correlated with disease activity assessed by SLEDAI score. SPMs including PD1 and RvE1 as well as their precursors, 17-HDHA and 18-HEPE, were identified in plasma and serum samples from SLE patients. Plasma levels of 17-HDHA, as well as serum levels of PD1, 17-HDHA, and 18-HEPE tended to be reduced in SLE (table 1). The SLE patients with a history of nephritis had significantly lower levels of DHA (p=0.03), EPA (p=0.05), 18-HEPE (p=0.03), and 17-HDHA (p=0.04) than SLE patients without nephritis.

Abstract 3 Table 1

Metabolipidomics of SLE and control serum

Conclusions SLE patients have lower levels of circulating EPA and DHA, the substrates for SPMs, relative to individuals without SLE. Lower levels of these PUFAs and some SPMs are associated with history of nephritis. Additionally, the levels of PD1, 17-HDHA, and 18-HEPE were measurable in SLE serum and plasma and tended to be reduced, especially in subjects with lupus nephritis. SPMs suppress the production of inflammatory mediators and promote resolution of inflammation. The lower levels of PUFAs and SPMs could contribute to the likelihood of developing lupus nephritis. Further evaluation of this relationship is warranted.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.